Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbuster ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management ... with three of Lilly's insulin products, including Humalog and Lyumjev ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and differentiate its products to stay ahead of the competition.

Eli Lilly and Company ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth ...

Competitors are developing their own innovative treatments, which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and ...

As the creator of the blockbuster weight-loss drug Zepbound, and the blockbuster type 2 diabetes drug ... to unrelenting demand. Eli Lilly (NYSE: LLY) sells many products across treatment areas ...